

PRESS RELEASE
Uppsala
December 18, 2008

Lyftet Holding B.V. requests an extra shareholders' meeting in Q-Med AB

The board of directors in Q-Med AB has received from Lyftet Holding B.V. a request for summoning of an extra shareholders' meeting for election of a new board of directors, subject to the limitations set out in Q-Med's articles of association.

As soon as a date for a shareholders' meeting has been settled, January 2, 2009 at the latest, a press release will be distributed and a notice will be published in Svenska Dagbladet, Upsala Nya Tidning and Post- och Inrikes Tidningar (Swedish Official Gazette). Information will also be available on the corporate web site.

Queries should be addressed to:

Pia Rudengren, Chairman of the Board
Mobile: +46 (0)706 242041 or +46 (0)768 161490

Q-Med AB is a rapidly growing and profitable biotechnology/medical device company. The company develops, manufactures, markets, and sells primarily medical implants. The majority of the products are based on the company's patented technology, **NASHA™**, for the production of stabilized non-animal hyaluronic acid. The product portfolio today contains: **Restylane®** for filling lines and folds, contouring and creating volume in the face, **Macrolane™** for body contouring, **Durolane™** for the treatment of osteoarthritis of the hip and knee joints, **Deflux®** for the treatment of vesicoureteral reflux, VUR, (a malformation of the urinary bladder) in children, and **Solesta™** for the treatment of fecal incontinence. Sales are made through the company's own subsidiaries or distributors in over 70 countries. Q-Med today has just over 700 coworkers, with close to 500 at the company's head office and production facility in Uppsala, Sweden. Q-Med AB is listed in the Mid Cap segment of the OMX Nordic Exchange in Stockholm.

Q-Med AB (publ), Seminariegatan 21, SE-752 28 Uppsala, Sweden. Corporate identity number 556258-6882.
Tel: +46(0)18-474 90 00. Fax: +46(0)18-474 90 01. E-mail: info@q-med.com. Web: www.q-med.com.

In USA, Q-Med AB's affiliate is the wholly-owned subsidiary Q-Med Scandinavia, Inc.